The world’s first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events; The China new drug application submission…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.